Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation
Sponsor: Shahid Beheshti University of Medical Sciences
Summary
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
Official title: Investigating the Effect of Low-dose Extended-release Tacrolimus and Sirolimus on the Short-term Outcomes of Allograft Kidney Transplantation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-03-01
Completion Date
2026-07-01
Last Updated
2025-06-24
Healthy Volunteers
No
Conditions
Interventions
Rapamune Pill
Rapamiune Tablet 1mg daily plus Advograf plus prednisolone
Locations (1)
Nooshin Dalili
Tehran, Iran